Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins - PubMed (original) (raw)
. 2003 Feb 15;36(4):440-6.
doi: 10.1086/346153. Epub 2003 Jan 24.
Affiliations
- PMID: 12567301
- DOI: 10.1086/346153
Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins
Ebbing Lautenbach et al. Clin Infect Dis. 2003.
Abstract
This study sought to assess the impact of restricting use of vancomycin and third-generation cephalosporins on vancomycin-resistant enterococci (VRE) prevalence. All clinical enterococcal isolates identified at a large academic medical center during a 10-year period were analyzed. Changes in VRE prevalence after sequential restrictions on use of vancomycin and third-generation cephalosporins were evaluated. The correlation between antibiotic use and VRE prevalence was also investigated. Vancomycin use initially decreased by 23.9% but returned to preintervention levels by the end of the study. Third-generation cephalosporin use decreased by 85.8%. However, VRE prevalence increased steadily from 17.4% to 29.6% during the 10-year period (P<.001). Clindamycin use was significantly correlated with VRE prevalence. Restricting the use of vancomycin and third-generations cephalosporins had little impact on VRE prevalence. The association between clindamycin use and the prevalence of VRE suggests that restriction of this and perhaps other antianaerobic agents might be an important component of future antimicrobial interventions.
Similar articles
- The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci.
Kolar M, Urbanek K, Vagnerova I, Koukalova D. Kolar M, et al. J Clin Pharm Ther. 2006 Feb;31(1):67-72. doi: 10.1111/j.1365-2710.2006.00701.x. J Clin Pharm Ther. 2006. PMID: 16476122 - Emergence of resistance to chloramphenicol among vancomycin-resistant enterococcal (VRE) bloodstream isolates.
Lautenbach E, Gould CV, LaRosa LA, Marr AM, Nachamkin I, Bilker WB, Fishman NO. Lautenbach E, et al. Int J Antimicrob Agents. 2004 Feb;23(2):200-3. doi: 10.1016/j.ijantimicag.2003.09.011. Int J Antimicrob Agents. 2004. PMID: 15013047 - Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS).
Zhanel GG, Laing NM, Nichol KA, Palatnick LP, Noreddin A, Hisanaga T, Johnson JL, Hoban DJ; NAVRESS Group. Zhanel GG, et al. J Antimicrob Chemother. 2003 Sep;52(3):382-8. doi: 10.1093/jac/dkg352. Epub 2003 Jul 29. J Antimicrob Chemother. 2003. PMID: 12888592 - [Vancomycin resistant enterococci in the Netherlands].
Leavis HL, Willems RJ, Mascini EM, Vandenbroucke-Grauls CM, Bonten MJ. Leavis HL, et al. Ned Tijdschr Geneeskd. 2004 May 1;148(18):878-82. Ned Tijdschr Geneeskd. 2004. PMID: 15152389 Review. Dutch. - Optimizing therapy for vancomycin-resistant enterococci (VRE).
Linden PK. Linden PK. Semin Respir Crit Care Med. 2007 Dec;28(6):632-45. doi: 10.1055/s-2007-996410. Semin Respir Crit Care Med. 2007. PMID: 18095227 Review.
Cited by
- Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.
Epstein BJ, Gums JG. Epstein BJ, et al. Drugs. 2005;65(14):1949-71. doi: 10.2165/00003495-200565140-00004. Drugs. 2005. PMID: 16162020 Review. - Interventions to improve antibiotic prescribing practices for hospital inpatients.
Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, Gould IM, Ramsay CR, Michie S. Davey P, et al. Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD003543. doi: 10.1002/14651858.CD003543.pub4. Cochrane Database Syst Rev. 2017. PMID: 28178770 Free PMC article. Review. - Systematic analysis of the relationship between antibiotic use and extended-spectrum beta-lactamase resistance in Enterobacteriaceae in a French hospital: a time series analysis.
Vibet MA, Roux J, Montassier E, Corvec S, Juvin ME, Ngohou C, Lepelletier D, Batard E. Vibet MA, et al. Eur J Clin Microbiol Infect Dis. 2015 Oct;34(10):1957-63. doi: 10.1007/s10096-015-2437-3. Epub 2015 Jul 24. Eur J Clin Microbiol Infect Dis. 2015. PMID: 26205663 - Impact of formulary restriction with prior authorization by an antimicrobial stewardship program.
Reed EE, Stevenson KB, West JE, Bauer KA, Goff DA. Reed EE, et al. Virulence. 2013 Feb 15;4(2):158-62. doi: 10.4161/viru.21657. Epub 2012 Nov 15. Virulence. 2013. PMID: 23154323 Free PMC article. Review. - Clostridium difficile infection: a critical overview.
Missaghi B, Valenti AJ, Owens RC Jr. Missaghi B, et al. Curr Infect Dis Rep. 2008 May;10(3):165-73. doi: 10.1007/s11908-008-0028-5. Curr Infect Dis Rep. 2008. PMID: 18510876
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources